Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

CompletedNot a drug-phase studyMS (type not specified)NCT00630721

What it found

No results found

We found no results in the registry or in papers.

This trial finished 16 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • IFNbeta-1b

What it measured

Main measures

  • Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs' on their maturation and the capacity to present

    2 years

Other measures (1)

  • Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription.

    2 years

    Immune response

Who could take part

MS (type not specified) · 18 to 60

Show the full criteria

Inclusion criteria

* Confirmed diagnosis of MS * Age 18-60 years, inclusive * Expanded disability status of 0-6.5 * Give written informed consent prior to any testing under this protocol

Exclusion criteria

Not separately supplied in the registry.

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.

Loading reviews and guidelines…

Related trials

History

    1. Started

      Sept 2007

    2. Main results due

      May 2010

    3. Finished

      Mar 2011

    Assembled by software from public sources.